284 related articles for article (PubMed ID: 22828384)
1. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect.
Bielefeld EC; Tanaka C; Chen GD; Coling D; Li M; Henderson D; Fetoni AR
Anticancer Drugs; 2013 Jan; 24(1):43-51. PubMed ID: 22828384
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity of 12 mg/kg cisplatin in the Fischer 344/NHsd rat using multiple dosing strategies.
Harrison RT; Seiler BM; Bielefeld EC
Anticancer Drugs; 2016 Sep; 27(8):780-6. PubMed ID: 27467178
[TBL] [Abstract][Full Text] [Related]
3. Epicatechin protects the auditory organ by attenuating cisplatin-induced ototoxicity through inhibition of ERK.
Lee JS; Kang SU; Hwang HS; Pyun JH; Choung YH; Kim CH
Toxicol Lett; 2010 Dec; 199(3):308-16. PubMed ID: 20883750
[TBL] [Abstract][Full Text] [Related]
4. A low-dose regimen of cisplatin before high-dose cisplatin potentiates ototoxicity.
Harrison RT; DeBacker JR; Bielefeld EC
Laryngoscope; 2015 Feb; 125(2):E78-83. PubMed ID: 25267530
[TBL] [Abstract][Full Text] [Related]
5. Age-related hearing loss patterns in Fischer 344/NHsd rats with cisplatin-induced hearing loss.
Bielefeld EC
Hear Res; 2013 Dec; 306():46-53. PubMed ID: 24055622
[TBL] [Abstract][Full Text] [Related]
6. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats.
Huang X; Whitworth CA; Rybak LP
Otol Neurotol; 2007 Sep; 28(6):828-33. PubMed ID: 17450108
[TBL] [Abstract][Full Text] [Related]
7. Selective GSK-3beta inhibitors attenuate the cisplatin-induced cytotoxicity of auditory cells.
Park HJ; Kim HJ; Bae GS; Seo SW; Kim DY; Jung WS; Kim MS; Song MY; Kim EK; Kwon KB; Hwang SY; Song HJ; Park CS; Park RK; Chong MS; Park SJ
Hear Res; 2009 Nov; 257(1-2):53-62. PubMed ID: 19666099
[TBL] [Abstract][Full Text] [Related]
8. AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity.
Cooper LB; Chan DK; Roediger FC; Shaffer BR; Fraser JF; Musatov S; Selesnick SH; Kaplitt MG
Otol Neurotol; 2006 Jun; 27(4):484-90. PubMed ID: 16791039
[TBL] [Abstract][Full Text] [Related]
9. Changing the time intervals between cisplatin cycles alter its ototoxic side effect.
Bielefeld EC; Gonzalez A; DeBacker JR
Hear Res; 2021 May; 404():108204. PubMed ID: 33618164
[TBL] [Abstract][Full Text] [Related]
10. Chronotolerance for cisplatin ototoxicity in the rat.
Bielefeld EC; Markle A; DeBacker JR; Harrison RT
Hear Res; 2018 Dec; 370():16-21. PubMed ID: 30253329
[TBL] [Abstract][Full Text] [Related]
11. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
Lynch ED; Gu R; Pierce C; Kil J
Hear Res; 2005 Mar; 201(1-2):81-9. PubMed ID: 15721563
[TBL] [Abstract][Full Text] [Related]
12. Prevention of noise-induced hearing loss with Src-PTK inhibitors.
Harris KC; Hu B; Hangauer D; Henderson D
Hear Res; 2005 Oct; 208(1-2):14-25. PubMed ID: 15950415
[TBL] [Abstract][Full Text] [Related]
13. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells.
Kopke RD; Liu W; Gabaizadeh R; Jacono A; Feghali J; Spray D; Garcia P; Steinman H; Malgrange B; Ruben RJ; Rybak L; Van de Water TR
Am J Otol; 1997 Sep; 18(5):559-71. PubMed ID: 9303151
[TBL] [Abstract][Full Text] [Related]
14. Prevention of noise- and drug-induced hearing loss with D-methionine.
Campbell KC; Meech RP; Klemens JJ; Gerberi MT; Dyrstad SS; Larsen DL; Mitchell DL; El-Azizi M; Verhulst SJ; Hughes LF
Hear Res; 2007 Apr; 226(1-2):92-103. PubMed ID: 17224251
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 70 and cellular disturbances in cochlear cisplatin ototoxicity model.
García-Berrocal JR; Nevado J; González-García JA; Sánchez-Rodríguez C; Sanz R; Trinidad A; España P; Citores MJ; Ramírez-Camacho R
J Laryngol Otol; 2010 Jun; 124(6):599-609. PubMed ID: 20307356
[TBL] [Abstract][Full Text] [Related]
16. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss.
Wang J; Ladrech S; Pujol R; Brabet P; Van De Water TR; Puel JL
Cancer Res; 2004 Dec; 64(24):9217-24. PubMed ID: 15604295
[TBL] [Abstract][Full Text] [Related]
17. WR-2721 (Amifostine) ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects.
Church MW; Blakley BW; Burgio DL; Gupta AK
J Assoc Res Otolaryngol; 2004 Sep; 5(3):227-37. PubMed ID: 15185124
[TBL] [Abstract][Full Text] [Related]
18. Cochlear structure and function after round window application of ototoxins.
Bauer CA; Brozoski TJ
Hear Res; 2005 Mar; 201(1-2):121-31. PubMed ID: 15721567
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.
Borse V; Al Aameri RFH; Sheehan K; Sheth S; Kaur T; Mukherjea D; Tupal S; Lowy M; Ghosh S; Dhukhwa A; Bhatta P; Rybak LP; Ramkumar V
Cell Death Dis; 2017 Jul; 8(7):e2921. PubMed ID: 28703809
[TBL] [Abstract][Full Text] [Related]
20. Friend or foe? Effect of oral resveratrol on cisplatin ototoxicity.
Olgun Y; Kırkım G; Kolatan E; Kıray M; Bagrıyanık A; Olgun A; Kızmazoglu DC; Ellıdokuz H; Serbetcıoglu B; Altun Z; Aktas S; Yılmaz O; Günerı EA
Laryngoscope; 2014 Mar; 124(3):760-6. PubMed ID: 23900991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
